The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | The role of genetic instability in the pathogenesis of multiple myeloma
Masood Shammas, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on how genomics can inform clinicians on how multiple myeloma occurs and how it can be managed. Despite the heterogeneity of genomic aberrations that can result in multiple myeloma, genomics can predict the prognosis in patients, as well as the instability of disease progression. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
